Intelligence Β· Patent portfolio
Axsome Therapeutics Patents
Full USPTO pharma patent portfolio for Axsome Therapeutics β grant dates, expiration, and drug cross-links.
- Patents
- 162
- Expiring β€24m
- 0
Quick answer
Axsome Therapeutics has 162 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months β use filters for patent-cliff planning.
-
US 11129895
Pharmaceutical compositions comprising meloxicam
granted -
US 11129826
Bupropion as a modulator of drug activity
granted -
US 11123344
Bupropion as a modulator of drug activity
granted -
US 11123431
Pharmaceutical compositions comprising meloxicam
granted -
US 11110173
Pharmaceutical compositions comprising meloxicam
granted -
US 11077117
Pharmaceutical compositions comprising meloxicam
granted -
US 11045549
Pharmaceutical compositions comprising meloxicam
granted -
US 11020402
Use of reboxetine to treat narcolepsy
granted -
US 11020483
Pharmaceutical compositions comprising meloxicam
granted -
US 11013805
Pharmaceutical compositions comprising meloxicam
granted -
US 11013806
Pharmaceutical compositions comprising meloxicam
granted -
US 10987358
Pharmaceutical compositions comprising meloxicam
granted -
US 10940153
Pharmaceutical compositions comprising meloxicam
granted -
US 10933136
Pharmaceutical compositions comprising meloxicam
granted -
US 10933137
Pharmaceutical compositions comprising meloxicam
granted -
US 10918722
Pharmaceutical compositions comprising meloxicam
granted -
US 10905693
Pharmaceutical compositions comprising meloxicam
granted -
US 10894053
Pharmaceutical compositions comprising meloxicam
granted -
US 10821181
Pharmaceutical compositions comprising meloxicam
granted -
US 10821182
Pharmaceutical compositions comprising meloxicam
granted -
US 10799588
Pharmaceutical compositions comprising meloxicam
granted -
US 10780165
Pharmaceutical compositions comprising meloxicam
granted -
US 10780166
Pharmaceutical compositions comprising meloxicam
granted -
US 10758617
Pharmaceutical compositions comprising meloxicam
granted -
US 10758618
Pharmaceutical compositions comprising meloxicam
granted -
US 10729697
Pharmaceutical compositions comprising meloxicam
granted -
US 10729774
Pharmaceutical compositions comprising meloxicam
granted -
US 10729696
Pharmaceutical compositions comprising meloxicam
granted -
US 10729773
Pharmaceutical compositions comprising meloxicam
granted -
US 10722583
Pharmaceutical compositions comprising meloxicam
granted -
US 10702602
Pharmaceutical compositions comprising meloxicam
granted -
US 10702535
Pharmaceutical compositions comprising meloxicam
granted -
US 10695429
Pharmaceutical compositions comprising meloxicam
granted -
US 10695304
Dosage forms and methods for enantiomerically enriched or pure bupropion
granted -
US 10695430
Pharmaceutical compositions comprising meloxicam
granted -
US 10688185
Pharmaceutical compositions comprising meloxicam
granted -
US 10688102
Combination treatment for migraine and other pain
granted -
US 10653777
Pharmaceutical compositions comprising meloxicam
granted -
US 10583144
Pharmaceutical compositions comprising meloxicam
granted -
US 10583088
Pharmaceutical compositions comprising meloxicam
granted -
US 10561664
Pharmaceutical compositions comprising meloxicam
granted -
US 10537642
Pharmaceutical compositions comprising meloxicam
granted -
US 10532101
Pharmaceutical compositions comprising meloxicam
granted -
US 10517950
Pharmaceutical compositions comprising meloxicam
granted -
US 10512692
Pharmaceutical compositions comprising meloxicam
granted -
US 10512693
Pharmaceutical compositions comprising meloxicam
granted -
US 10485871
Pharmaceutical compositions comprising meloxicam
granted -
US 10471069
Pharmaceutical compositions comprising meloxicam
granted
Frequently asked questions
How many patents does Axsome Therapeutics have?
162 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Axsome Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory